GlassScriptPhysician profile
Keith Lechtenberg
NPI 1720060346
$12,557.50
in general payments reported to CMS, 2019-2025
45 companies · $1,830 in 2025
The $1,830 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,939 · 2020: $1,582 · 2021: $1,849 · 2022: $1,883 · 2023: $1,703 · 2024: $1,771 · 2025: $1,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,303.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,808.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,793.13 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,154.62 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $847.58 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $610.78 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $564.24 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Amarin Pharma, INC. | $414.91 | 2019-2022 | |
| Esperion Therapeutics, INC. | $413.25 | 2021-2025 | Nexletol |
| Abbott Laboratories | $375.86 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.83 | 2019-2025 | Jardiance |
| Amgen INC. | $347.31 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $340.73 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $324.85 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $318.97 | 2019-2022 | |
| Astellas Pharma US INC | $311.91 | 2019-2023 | Veozah, Myrbetriq |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Lechtenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.